Adverse effects: 3. Metabolic weight gain ≥7% of total body weight · schizophrenia
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic weight gain ≥7% of total body weight compared with RISPERIDONE (moderate certainty).
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · schizophrenia
1 finding from 1 review
Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · schizophrenia
1 finding from 1 review
Quality of life: substantial improvement · schizophrenia
1 finding from 1 review
Quality of life: substantial improvement · schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · schizophrenia
QUETIAPINE may leads to higher adverse effects: 1. Sedation compared with ZIPRASIDONE (low certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · schizophrenia
QUETIAPINE may leads to lower adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson… compared with ZIPRASIDONE (low certainty).
1 finding from 1 review
Adverse effects: 3. Metabolic weight gain ≥7% of total body weight · schizophrenia
QUETIAPINE probably leads to higher adverse effects: 3. Metabolic weight gain ≥7% of total body weight compared with ZIPRASIDONE (moderate certainty).
1 finding from 1 review
Adverse effects: 1. Sedation · schizophrenia
1 finding from 1 review
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · schizophrenia
QUETIAPINE showed no clear difference in adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson… compared with ARIPIPRAZOLE (low certainty).
1 finding from 1 review
Adverse effects: 3. Metabolic weight gain ≥7% of total body weight · schizophrenia
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic ‐ weight gain ≥7% of total body weight compared with ARIPIPRAZOLE (low certainty).
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · schizophrenia
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia
1 finding from 1 review
Behaviour: No clinically important response (as defined by the original studies) · patients with schizophrenia
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia
1 finding from 1 review
Global state: No clinically important response (as defined by the original studies) · patients with schizophrenia
1 finding from 1 review
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · patients with schizophrenia
ZOTEPINE showed no clear difference in adverse effects: Extrapyramidal effects ‐ use of antiparkinson… compared with REMOXIPRIDE (low certainty).
1 finding from 1 review
Behaviour: No clinically important response (as defined by the original studies) · patients with schizophrenia
1 finding from 1 review